ASH 2023 | High-sustained factor & non-factor replacement therapy: reducing treatment burden in hemophilia
Glaivy Batsuli
• 11 Dec 2023
In this video, Glaivy Batsuli, MD, Stanford University, Stanford, CA, shares insights into how novel high-sustained factor and non-factor replacement therapies aim to improve efficacy and reduce treatment burden in patients with hemophilia. Extended half-life products allow for a reduction in the frequency of injections, and Dr Batsuli also comments on how the increased use of subcutaneous injection with non-factor therapies can reduce treatment burden in this setting. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
